Abstract
Non-alcoholic fatty liver disease (NAFLD) is a complex disease involving alterations in multiple biological processes regulated by the interactions between obesity, genetic background and environmental factors including the microbiome. To decipher hepatic steatosis (HS) pathogenesis by excluding critical confounding factors including genetic variants, obesity and diabetes, we characterized 56 heterogeneous NAFLD patients by generating multi-omics data including oral and gut metagenomics as well as plasma metabolomics and inflammatory proteomics data. We explored the dysbiosis in the oral and gut microbiome and revealed host-microbiome interactions based on global metabolic and inflammatory processes. We integrated this multi-omics data using the biological network and identified HS’s key features using multi-omics data. We finally predicted HS using these key features and validated our findings in a validation dataset, where we characterized 22 subjects with varying degree of HS.
Significance statement The oral and gut microbiota alterations have been linked to NAFLD. There is a lack of data on multi-omics characteristics of hepatic steatosis by exclusion of major confounding factors of obesity and metabolic syndrome. We observed that the oral and gut microbiota remodelling starts at early stages of the NAFLD spectrum, independent of obesity and metabolic syndrome. Our analysis suggested that the bacterial diversity is correlated with multi-omics signatures in NAFLD and our predictive model created based on multi-omics variables can successfully predict hepatic steatosis. The components of the multi-omics signatures may serve as biomarkers and can be pharmaceutically targeted. Future clinical trials with microbiota manipulation could consider intervention at early stages of NAFLD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was financially supported by ScandiBio Therapeutics and Knut and Alice Wallenberg Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Koc University ethics committee approved the study (Decision No: 2018.351.IRB1.043, Decision Date: 15 May 2019).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Emails: mujdat.zeybel{at}nottingham.ac.uk; oaltay{at}kth.se; muhammad.arif{at}scilifelab.se; mgonenli{at}ku.edu.tr; makyildiz{at}ku.edu.tr; mengnan.shi{at}scilifelab.se; hasanturkez{at}yahoo.com; bsaglam{at}kuh.ku.edu.tr; byigit{at}ku.edu.tr; bulukan18{at}ku.edu.tr; dural{at}ku.edu.tr; xiangyu.li{at}scilifelab.se; cheng.zhang{at}scilifelab.se; saeed.shoaie{at}kcl.ac.uk; nielsenj{at}chalmers.se; mathias.uhlen{at}scilifelab.se; jan.boren{at}wlab.gu.se; adilm{at}scilifelab.se
Data Availability
All data associated with this study are available in the main text or the supplementary materials.